On Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) opened higher 4.18% from the last session, before settling in for the closing price of $29.40. Price fluctuations for XENE have ranged from $29.20 to $46.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 35.90% annually for the last half of the decade. Company’s average yearly earnings per share was noted -35.01% at the time writing. With a float of $74.20 million, this company’s outstanding shares have now reached $76.42 million.
In an organization with 327 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Xenon Pharmaceuticals Inc (XENE) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xenon Pharmaceuticals Inc is 3.05%, while institutional ownership is 97.31%. The most recent insider transaction that took place on Jan 24 ’25, was worth 903,214. In this transaction PRESIDENT & CEO of this company sold 22,468 shares at a rate of $40.20, taking the stock ownership to the 31,302 shares. Before that another transaction happened on Jan 27 ’25, when Company’s PRESIDENT & CEO sold 16,315 for $40.50, making the entire transaction worth $660,806. This insider now owns 31,302 shares in total.
Xenon Pharmaceuticals Inc (XENE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.25% during the next five years compared to -14.28% drop over the previous five years of trading.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Check out the current performance indicators for Xenon Pharmaceuticals Inc (XENE). In the past quarter, the stock posted a quick ratio of 17.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -4.52 in one year’s time.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
Let’s dig in a bit further. During the last 5-days, its volume was 1.22 million. That was better than the volume of 0.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.20%. Additionally, its Average True Range was 1.78.
During the past 100 days, Xenon Pharmaceuticals Inc’s (XENE) raw stochastic average was set at 17.16%, which indicates a significant decrease from 34.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.25% in the past 14 days, which was higher than the 38.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.73, while its 200-day Moving Average is $39.60. However, in the short run, Xenon Pharmaceuticals Inc’s stock first resistance to watch stands at $32.25. Second resistance stands at $33.86. The third major resistance level sits at $36.21. If the price goes on to break the first support level at $28.29, it is likely to go to the next support level at $25.94. Assuming the price breaks the second support level, the third support level stands at $24.33.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Key Stats
There are currently 76,543K shares outstanding in the company with a market cap of 2.34 billion. Presently, the company’s annual sales total 0 K according to its annual income of -234,330 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -65,690 K.
